Nevertheless, no significant relationship was observed between PRDX1 expression and OS in patients with CCA (HR = 1.23, 95% CI: 0.32-4.69, P = 0.757, random effects), ESCC (HR = 0.82, 95% CI: 0.45-1.50, P = 0.521, random effects), and BC (HR = 0.83, 95% CI: 0.66-1.04, P = 0.111, fixed effects). This evidence concerns the gene PRDX1 and cholangiocarcinoma.